Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Jiangsu Hengrui Forms Global Clinical Collaboration with LSK BioPharma

publication date: Oct 23, 2018

Jiangsu Hengrui Medicine and LSK BioPharma of Salt Lake City announced a global test that combines Hengrui's PD-1 candidate with LSKB's rivoceranib, a VEGFR-2 inhibitor, as a treatment for hepatocellular carcinoma. Hengrui's PD-1 mAb, camrelizumab, is currently under NDA review in China for classic Hodgkin's Lymphoma. Hengrui also owns China rights to rivoceranib, where it is available as Aitan® as a treatment for gastric cancer. LSKB holds ex-China rights to the drug. More details....

Stock Symbol: (SHA: 600276)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.